As the COVID-19 pandemic progresses and continues to affect everyday life around the world, the path that lies ahead for the MedTech industry and the search for effective therapeutics and vaccines remains hard to predict.
Based on prelim Q220 MedTech Company results, SVB Leerink expects May/June COVID recovery to exceed expectations noting elective procedure shutdowns are regionalized and halts are not expected to be as bad or prolonged as in March/April. SVBLeerink Medical Supplies and Devices
With 4 of the leading vaccine candidates expected to enter Phase 3 studies in July (Sinovac, Moderna, BioNTech/PFE, CanSino), Phase 2 data could be reported in summer/fall 2020. If +, WFS says it could be a catalyst for some medtech sectors in recovery of elective procedures.
A survey assessing public perceptions towards resuming elective surg found out of 722 people 61% were concerned w/ contracting COVID-19 during surg. Overall, 57% would have surgery at a hospital vs outpatient and 27% would undergo surg in the first mo of reopening. J Arthroplasty
The European Commission published a document about the preparedness of health systems in Europe for future COVID-19 outbreaks. Topics comprise testing, contact tracing, surveillance, accessibility of medical devices and capacity measures.
WFS reports US elective procedures for the week ending July 3rd were down -45% compared to the pre-COVID baseline w/ negative impact by the July 4th holiday. Also, because of data latency, WFS believes the actual decline may be in the -30 to -33% range. WFS MedTech
3M announced it is working w/ MIT researchers to develop a paper-based, rapid test to detect the virus that causes COVID-19 in minutes at point-of-care, w/ the potential to manufacture millions of tests per day.
Based on JNJ and Abbott Q2 results Jefferies believes underlying demand for elective procedures post-COVID shutdowns may be below normal through at least the end of the yr and notes their hospital tracking data shows the recovery losing steam. Jefferies Medical Devices & Supplies
Based on JNJ and Abbott Q2 results WFS feels Q2 recovery is tracking ahead of expectations due to economies opening earlier than expected globally, Q3 recovery may be stronger than expected, concern about a 2nd COVID wave have lessened and Q4 will approach normal. WFS MedTech